NCT05566782Active, not recruiting
Cross-sectoral Rehabilitation After Stroke (CRES)
Source: ClinicalTrials.gov · Last updated 15 Nov 2024
Brief summary (registry, in English)
Prospective cohort study during post stroke rehabilitation in hospital and municipality. Participants will be measured with accelerometers, tests in relation to physical function and qualitative interviews.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 117 (estimated)
- First submitted
- 26 Sept 2022
- Start date
- 23 Jan 2022
- Primary completion date
- 5 Oct 2025
- Lead sponsor
- Nordsjaellands Hospital
- Diseases
- Stroke
- NCT number
- NCT05566782
What you commit to
- Study type: Observational
- Planned participants: 117
- From 23 Jan 2022 to the primary completion date, 5 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Poor Danish language skill;
- Patients refusing any rehabilitation or medically assessed as inevitably dying within 12 weeks;
Who the study is looking for
- 18 years of age;
- Hospitalized at Nordsjællands Hospital (NOH) with acute stroke;
- Discharged from the Department of Neurology NOH with a general rehabilitation plan to one of the eight surrounding municipalities (Hillerød, Allerød, Gribskov, Helsingør, Hørsholm, Halsnæs, Frederikssund Fredensborg);
- able to give written informed consent;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nordsjællands Hospital Department of Neurology Coordinator of this site? Confirm its status | Hillerød | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.